You searched for: multicentrični (Slovenska - Engelska)

mediana starosti v multicentrični študiji je bila 40 let (obseg od 5 do 73).
the median age in the multicentre study was 40 years (age range 5 to 73).

imunogenost cepiva prevenar so raziskali v odprti multicentrični študiji pri 49 dojenčkih z anemijo srpastih celic.
the immunogenicity of prevenar has been investigated in an open-label, multicenter study in 49 infants with sickle cell disease.

zdravilo blincyto so ocenili v odprti, multicentrični študiji ii. faze z eno samo skupino s 189 bolniki.
blincyto was evaluated in an open-label, multicentre, single-arm phase ii study of 189 patients.

spodaj opisani podatki se nanašajo na 438 bolnikov, ki so bili v odprti multicentrični študiji izpostavljeni zdravilu tasigna.
the data described below reflect exposure to tasigna in 438 patients in an open-label multicentre study.

v multicentrični, dvojno slepi 12-tedenski faktorski študiji je 4-tedenska uporaba zdravila trevaclyn
in a multicentre, double-blind, 12-week factorial study, trevaclyn 1,000 mg/20 mg co-administered with simvastatin, when compared with simvastatin alone or trevaclyn 1,000 mg/20 mg alone, for

pri bolnikih s cervikalno distonijo so izvedli dve randomizirani, multicentrični, dvojno slepi študiji iii faze, kontrolirani s placebom.
two phase iii randomised, multicentre, double-blind, placebo-controlled studies were conducted in patients with cervical dystonia.

v 12-tedenski randomizirani, dvojno slepi, multicentrični študiji so placebo in pegvisomant primerjali pri 112 bolnikih z akromegalijo.
acromegalic patients (n=112) have been treated in a 12-week, randomised, double-blind, multicentre study comparing placebo and pegvisomant.

učinkovitost in varnost degareliksa so ovrednotili v odprti, multicentrični, randomizirani študiji s paralelnimi skupinami, kontrolirani z aktivnim primerjalnim zdravilom.
the efficacy and safety of degarelix was evaluated in an open-label, multi-centre, randomised, active comparator controlled, parallel-group study.

pri bolnikih v multicentrični študiji je prišlo do relapsa po 1–4 predhodih krogih zdravljenja in pri 5 bolnikih je prišlo do relapsa po transplantaciji zarodnih celic.
patients in the multicentre study had relapsed following 1-4 prior therapy regimens and 5 patients had relapsed following stem cell transplantation.

učinkovitost zdravila eperzan so ocenili v 3-letni randomizirani, dvojno slepi multicentrični študiji (n = 299).
the efficacy of eperzan was evaluated in a 3-year, randomised, double-blind, multicentre study (n = 299).

raziskava rely-able (dolgotrajen, multicentrični podaljšek zdravljenja z dabigatranom pri bolnikih z atrijsko fibrilacijo po končani raziskavi re-ly)
rely-able (long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the re-ly trial)

izvedeni sta bili dve randomizirani, dvojno slepi, multicentrični s placebom nadzorovani ključni študiji 3. faze (aries- 1 in 2).
21 two randomised, double-blind, multi-centre, placebo controlled, phase 3 pivotal studies were conducted (aries-1 and 2).

v dvojno slepi, kontrolirani, multicentrični študiji pri bolnikih z aktivnim revmatoidnim artritisom (sc-ii) so radiološko ocenjevali subkutano dani tocilizumab.
the radiographic response of subcutaneous administered tocilizumab was assessed in a double-blind, controlled, multicenter study in patients with active ra (sc-ii).

učinkovitost rivastigmina pri demenci, povezani s parkinsonovo boleznijo so pokazali v 24-tedenski multicentrični, dvojno slepi, s placebom nadzorovani osrednji študiji in naknadni 24-tedenski odprti fazi.
the efficacy of rivastigmine in dementia associated with parkinson's disease has been demonstrated in a 24-week multicentre, double-blind, placebo-controlled core study and its 24-week open-label extension phase.

klinične študije pri demenci, povezani s parkinsonovo boleznijo učinkovitost rivastigmina pri demenci, povezani s parkinsonovo boleznijo, so pokazali v 24- tedenski multicentrični, dvojno slepi, s placebom kontrolirani osnovni študiji in njeni 24- tedenski odprti podaljšani fazi.
19 clinical studies in dementia associated with parkinson’ s disease the efficacy of rivastigmine in dementia associated with parkinson’ s disease has been demonstrated in a 24-week multicentre, double-blind, placebo-controlled core study and its 24-week open-label extension phase.